Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $8.75.
PYXS has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Wedbush raised their target price on shares of Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Finally, HC Wainwright upped their price target on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, September 10th.
Check Out Our Latest Report on PYXS
Pyxis Oncology Trading Down 4.2%
Shares of PYXS stock opened at $1.81 on Thursday. The stock has a market capitalization of $150.97 million, a price-to-earnings ratio of -1.28 and a beta of 1.37. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55. The stock’s 50-day moving average price is $2.66 and its 200-day moving average price is $2.16.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). As a group, research analysts predict that Pyxis Oncology will post -1.21 EPS for the current fiscal year.
Institutional Trading of Pyxis Oncology
A hedge fund recently raised its position in Pyxis Oncology stock. Renaissance Technologies LLC lifted its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) by 22.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 888,680 shares of the company’s stock after acquiring an additional 160,300 shares during the period. Renaissance Technologies LLC owned 1.41% of Pyxis Oncology worth $1,297,000 at the end of the most recent quarter. 39.07% of the stock is currently owned by institutional investors and hedge funds.
About Pyxis Oncology
Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.
Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.
See Also
- Five stocks we like better than Pyxis Oncology
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
